Curative-Intent Aggressive Treatment Improves Survival in Elderly Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma and High Comorbidity Index

Jin Hua Chen, Yu Chun Yen, Hsuan Chia Yang, Shing Hwa Liu, Sheng Po Yuan, Li Li Wu, Fei Peng Lee, Kuan Chou Lin, Ming Tang Lai, Chia Che Wu, Tsung Ming Chen, Chia Lun Chang, Jyh Ming Chow, Yi Fang Ding, Szu Yuan Wu

研究成果: 雜誌貢獻文章

23 引文 (Scopus)

摘要

For locally advanced head and neck squamous cell carcinoma (HNSCC), therapeutic decisions depend on comorbidity or age. We estimated the treatment outcomes of patients with different Charlson comorbidity index (CCI) scores and ages to determine whether aggressive treatment improves survival. Data from the Taiwan National Health Insurance and cancer registry databases were analyzed, and we included >20-year-old patients with American Joint Committee on Cancer (AJCC) stage III or IV HNSCC (International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9) undergoing surgery, chemotherapy (CT), radiotherapy (RT), concurrent chemoradiotherapy (CCRT), sequential CT and RT, or surgery with adjuvant treatment. The exclusion criteria were a past cancer history, distant metastasis, AJCC stage I or II, missing sex data, an age <20 years, nasopharyngeal cancer, in situ carcinoma, sarcoma, and HNSCC recurrence. The index date was the date of first HNSCC diagnosis, and comorbidities were scored using the CCI. The enrolled patients were categorized into Group 1 (curative-intent aggressive treatments) and Group 2 (best supportive care or palliative treatments). We enrolled 21,174 stage III or IV HNSCC patients without distant metastasis (median follow-up, 3.25 years). Groups 1 and 2 comprised 18,584 and 2232 patients, respectively. After adjustment for age, sex, and clinical stage, adjusted hazard ratios (95% confidence intervals) of overall death in Group 1 were 0.33 (0.31-0.35), 0.34 (0.31-0.36), and 0.37 (0.28-0.49), and those of all-cause death among patients undergoing curative surgical aggressive treatments were 1.13 (0.82-1.55), 0.67 (0.62-0.73), and 0.49 (0.46-0.53) for CCI scores of ≥10, 5 to 9, and
原文英語
文章編號e3268
期刊Medicine (United States)
95
發行號14
DOIs
出版狀態已發佈 - 四月 1 2016

指紋

Comorbidity
Survival
Neoplasms
Radiotherapy
Therapeutics
Nasopharyngeal Neoplasms
Neoplasm Metastasis
Drug Therapy
Carcinoma in Situ
National Health Programs
Chemoradiotherapy
International Classification of Diseases
Taiwan
Palliative Care
Sarcoma
Registries
Carcinoma, squamous cell of head and neck
Cause of Death
Databases
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

引用此文

@article{d9e3a12570b747f28c283cbd90128e17,
title = "Curative-Intent Aggressive Treatment Improves Survival in Elderly Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma and High Comorbidity Index",
abstract = "For locally advanced head and neck squamous cell carcinoma (HNSCC), therapeutic decisions depend on comorbidity or age. We estimated the treatment outcomes of patients with different Charlson comorbidity index (CCI) scores and ages to determine whether aggressive treatment improves survival. Data from the Taiwan National Health Insurance and cancer registry databases were analyzed, and we included >20-year-old patients with American Joint Committee on Cancer (AJCC) stage III or IV HNSCC (International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9) undergoing surgery, chemotherapy (CT), radiotherapy (RT), concurrent chemoradiotherapy (CCRT), sequential CT and RT, or surgery with adjuvant treatment. The exclusion criteria were a past cancer history, distant metastasis, AJCC stage I or II, missing sex data, an age <20 years, nasopharyngeal cancer, in situ carcinoma, sarcoma, and HNSCC recurrence. The index date was the date of first HNSCC diagnosis, and comorbidities were scored using the CCI. The enrolled patients were categorized into Group 1 (curative-intent aggressive treatments) and Group 2 (best supportive care or palliative treatments). We enrolled 21,174 stage III or IV HNSCC patients without distant metastasis (median follow-up, 3.25 years). Groups 1 and 2 comprised 18,584 and 2232 patients, respectively. After adjustment for age, sex, and clinical stage, adjusted hazard ratios (95{\%} confidence intervals) of overall death in Group 1 were 0.33 (0.31-0.35), 0.34 (0.31-0.36), and 0.37 (0.28-0.49), and those of all-cause death among patients undergoing curative surgical aggressive treatments were 1.13 (0.82-1.55), 0.67 (0.62-0.73), and 0.49 (0.46-0.53) for CCI scores of ≥10, 5 to 9, and",
author = "Chen, {Jin Hua} and Yen, {Yu Chun} and Yang, {Hsuan Chia} and Liu, {Shing Hwa} and Yuan, {Sheng Po} and Wu, {Li Li} and Lee, {Fei Peng} and Lin, {Kuan Chou} and Lai, {Ming Tang} and Wu, {Chia Che} and Chen, {Tsung Ming} and Chang, {Chia Lun} and Chow, {Jyh Ming} and Ding, {Yi Fang} and Wu, {Szu Yuan}",
year = "2016",
month = "4",
day = "1",
doi = "10.1097/MD.0000000000003268",
language = "English",
volume = "95",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - Curative-Intent Aggressive Treatment Improves Survival in Elderly Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma and High Comorbidity Index

AU - Chen, Jin Hua

AU - Yen, Yu Chun

AU - Yang, Hsuan Chia

AU - Liu, Shing Hwa

AU - Yuan, Sheng Po

AU - Wu, Li Li

AU - Lee, Fei Peng

AU - Lin, Kuan Chou

AU - Lai, Ming Tang

AU - Wu, Chia Che

AU - Chen, Tsung Ming

AU - Chang, Chia Lun

AU - Chow, Jyh Ming

AU - Ding, Yi Fang

AU - Wu, Szu Yuan

PY - 2016/4/1

Y1 - 2016/4/1

N2 - For locally advanced head and neck squamous cell carcinoma (HNSCC), therapeutic decisions depend on comorbidity or age. We estimated the treatment outcomes of patients with different Charlson comorbidity index (CCI) scores and ages to determine whether aggressive treatment improves survival. Data from the Taiwan National Health Insurance and cancer registry databases were analyzed, and we included >20-year-old patients with American Joint Committee on Cancer (AJCC) stage III or IV HNSCC (International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9) undergoing surgery, chemotherapy (CT), radiotherapy (RT), concurrent chemoradiotherapy (CCRT), sequential CT and RT, or surgery with adjuvant treatment. The exclusion criteria were a past cancer history, distant metastasis, AJCC stage I or II, missing sex data, an age <20 years, nasopharyngeal cancer, in situ carcinoma, sarcoma, and HNSCC recurrence. The index date was the date of first HNSCC diagnosis, and comorbidities were scored using the CCI. The enrolled patients were categorized into Group 1 (curative-intent aggressive treatments) and Group 2 (best supportive care or palliative treatments). We enrolled 21,174 stage III or IV HNSCC patients without distant metastasis (median follow-up, 3.25 years). Groups 1 and 2 comprised 18,584 and 2232 patients, respectively. After adjustment for age, sex, and clinical stage, adjusted hazard ratios (95% confidence intervals) of overall death in Group 1 were 0.33 (0.31-0.35), 0.34 (0.31-0.36), and 0.37 (0.28-0.49), and those of all-cause death among patients undergoing curative surgical aggressive treatments were 1.13 (0.82-1.55), 0.67 (0.62-0.73), and 0.49 (0.46-0.53) for CCI scores of ≥10, 5 to 9, and

AB - For locally advanced head and neck squamous cell carcinoma (HNSCC), therapeutic decisions depend on comorbidity or age. We estimated the treatment outcomes of patients with different Charlson comorbidity index (CCI) scores and ages to determine whether aggressive treatment improves survival. Data from the Taiwan National Health Insurance and cancer registry databases were analyzed, and we included >20-year-old patients with American Joint Committee on Cancer (AJCC) stage III or IV HNSCC (International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9) undergoing surgery, chemotherapy (CT), radiotherapy (RT), concurrent chemoradiotherapy (CCRT), sequential CT and RT, or surgery with adjuvant treatment. The exclusion criteria were a past cancer history, distant metastasis, AJCC stage I or II, missing sex data, an age <20 years, nasopharyngeal cancer, in situ carcinoma, sarcoma, and HNSCC recurrence. The index date was the date of first HNSCC diagnosis, and comorbidities were scored using the CCI. The enrolled patients were categorized into Group 1 (curative-intent aggressive treatments) and Group 2 (best supportive care or palliative treatments). We enrolled 21,174 stage III or IV HNSCC patients without distant metastasis (median follow-up, 3.25 years). Groups 1 and 2 comprised 18,584 and 2232 patients, respectively. After adjustment for age, sex, and clinical stage, adjusted hazard ratios (95% confidence intervals) of overall death in Group 1 were 0.33 (0.31-0.35), 0.34 (0.31-0.36), and 0.37 (0.28-0.49), and those of all-cause death among patients undergoing curative surgical aggressive treatments were 1.13 (0.82-1.55), 0.67 (0.62-0.73), and 0.49 (0.46-0.53) for CCI scores of ≥10, 5 to 9, and

UR - http://www.scopus.com/inward/record.url?scp=84964575515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964575515&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000003268

DO - 10.1097/MD.0000000000003268

M3 - Article

C2 - 27057882

AN - SCOPUS:84964575515

VL - 95

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 14

M1 - e3268

ER -